Scinopharm Taiwan Ltd. (1789)
TWSE
19.10
+0.15 (+0.79%)
Closed
Oct 8, 2026
Day's Range
18.9019.40
52 wk Range
16.7029.10
Financial Statements - 1789 - Scinopharm Taiwan Ltd.
Revenue
3.16B▼ 7.1%
Net Income
136.95M▼ 59.6%Net Margin 4.3%
EBITDA
673.92M▼ 26.0%
Free Cash Flow
299.67M▼ 35.2%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 3.16B | 3.40B | 3.18B | 3.26B | 2.76B | 3.08B |
| Cost of Goods | 2.06B | 2.10B | 1.97B | 2.01B | 1.48B | 1.76B |
| Gross Profit | 1.09B | 1.30B | 1.21B | 1.25B | 1.28B | 1.31B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 108.86M | 322.70M | 314.42M | 405.63M | 288.74M | 375.50M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 147.37M | 413.01M | 348.84M | 437.96M | 302.28M | 358.50M |
| Income Tax | 10.42M | 73.66M | 61.78M | 84.74M | 58.81M | 76.43M |
| Net Income | 136.95M | 339.35M | 287.05M | 353.21M | 243.47M | 282.06M |
| EPS Basic | 0.17 | 0.43 | 0.36 | 0.45 | 0.31 | 0.36 |
| EPS Diluted | 0.17 | 0.43 | 0.36 | 0.45 | 0.31 | 0.36 |
| Basic Shares Outstanding | 790.73M | 790.73M | 790.73M | 790.73M | 790.73M | 790.73M |
| Diluted Shares Outstanding | 790.73M | 790.73M | 790.73M | 790.73M | 790.73M | 790.73M |
| Ebit | 157.24M | 421.10M | 357.98M | 445.87M | 308.83M | 373.67M |
| Ebitda | 673.92M | 911.04M | 819.08M | 885.47M | 690.49M | 766.64M |
| Net Income Continuous Operations | 147.37M | 413.01M | 348.84M | 437.96M | 302.28M | 358.50M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
